Literature DB >> 30032312

Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening.

T Ackerman1, A Geerts2, H Van Vlierberghe2, J De Backer3, K François4.   

Abstract

We tried to identify structural and functional liver aberrances in a palliated Fontan population and sought to determine useful screening modalities, in order to propose a screening protocol to detect patients at risk. Twenty nine patients, median age 23.7 years (interquartile range (IQR) 20.5-27.2) and median Fontan interval 19.7 years (IQR 4.5-21.4), were prospectively studied with echocardiography, blood analysis (including serum fibrosis scores Forns, APRI and FIB4), liver imaging (ultrasound (US), Doppler), and shear wave elastography to determine liver stiffness (LS). Laboratory tests predominantly showed abnormal values for gamma-glutamyltransferase. Forns index indicated moderate fibrosis in 29% of patients and correlated with Fontan interval (p = 0.034). US liver morphology was deviant in 46% of patients, with surface nodularity in 21% and nodular hyperplasia in 29%. Doppler assessment of flow velocities was within normal ranges for most patients. LS (mean 10.4 ± 3.7 kPa) was elevated in 96% of our population and higher LS values were significantly related to longer Fontan interval (p = 0.018). Adolescent and adult Fontan patients show moderate signs of liver dysfunction. Usefulness of serum parameters and fibrosis scores in post-Fontan screening remains ambiguous. The high percentage of morphologic liver changes in palliated patients supports the use of US in periodic follow-up. LS likely overestimates fibrosis due to liver congestion, arguing for the need of validation through sequential measurements. Screening should minimally encompass US assessment in combination with selective liver fibrosis scores. The role of LS measurement in Fontan follow-up and liver screening needs to be further elucidated.

Entities:  

Keywords:  Cardiac hepatopathy; Elastography; Fontan circulation; Screening; Serum markers; Univentricular heart

Mesh:

Year:  2018        PMID: 30032312     DOI: 10.1007/s00246-018-1937-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  43 in total

1.  Hemodynamic phenotype of the failing Fontan in an adult population.

Authors:  Camden L Hebson; Nancy M McCabe; Robert W Elder; William T Mahle; Michael McConnell; Brian E Kogon; Emir Veledar; Maan Jokhadar; Robert N Vincent; Anurag Sahu; Wendy M Book
Journal:  Am J Cardiol       Date:  2013-09-25       Impact factor: 2.778

Review 2.  Heart Disease and the Liver: Pathologic Evaluation.

Authors:  Anne Knoll Koehne de Gonzalez; Jay H Lefkowitch
Journal:  Gastroenterol Clin North Am       Date:  2017-06       Impact factor: 3.806

3.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

4.  Non-invasive assessment of liver fibrosis in patients after the Fontan operation.

Authors:  Takeshi Furukawa; Katsumi Akimoto; Masahiro Ohtsuki; Keiko Sato; Mitsuyoshi Suzuki; Ken Takahashi; Masahiko Kishiro; Toshiaki Shimizu; Shiori Kawasaki
Journal:  Pediatr Int       Date:  2011-12       Impact factor: 1.524

5.  Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery.

Authors:  Matthew C Schwartz; Lisa M Sullivan; Andrew C Glatz; Elizabeth Rand; Pierre Russo; David J Goldberg; Jonathan J Rome; Meryl S Cohen
Journal:  Pediatr Cardiol       Date:  2012-06-14       Impact factor: 1.655

6.  Impact of liver disease after the fontan operation.

Authors:  Ian Lindsay; Joy Johnson; Melanie D Everitt; James Hoffman; Anji T Yetman
Journal:  Am J Cardiol       Date:  2014-10-30       Impact factor: 2.778

7.  Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure.

Authors:  Luiz Antônio Brito Arruda Vasconcelos; Eros Antônio de Almeida; Luiz Felipe Bachur
Journal:  Arq Bras Cardiol       Date:  2007-05       Impact factor: 2.000

8.  Hepatic Abnormalities Are Present Before and Early After the Fontan Operation.

Authors:  Matthew C Schwartz; Andrew C Glatz; Kaitlyn Daniels; David J Goldberg; Elizabeth Rand; Monica S Epelman; Meryl S Cohen
Journal:  Ann Thorac Surg       Date:  2015-09-04       Impact factor: 4.330

9.  Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study.

Authors:  Robert W Elder; Nancy M McCabe; Camden Hebson; Emir Veledar; Rene Romero; Ryan M Ford; William T Mahle; Brian E Kogon; Anurag Sahu; Maan Jokhadar; Michael E McConnell; Wendy M Book
Journal:  Int J Cardiol       Date:  2013-07-09       Impact factor: 4.164

10.  Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders.

Authors:  A H Cromme-Dijkhuis; J Hess; K Hählen; C M Henkens; M T Bink-Boelkens; A A Eygelaar; E Bos
Journal:  J Thorac Cardiovasc Surg       Date:  1993-12       Impact factor: 5.209

View more
  1 in total

1.  Hepatic and splenic sonographic and sonoelastographic findings in pulmonary arterial hypertension.

Authors:  İlhan Hekimsoy; Burçin Kibar Öztürk; Hatice Soner Kemal; Meral Kayıkçıoğlu; Ömer Faruk Dadaş; Gülgün Kavukçu; Mehmet Nurullah Orman; Sanem Nalbantgil; Sadık Tamsel; Hakan Kültürsay; Süha Süreyya Özbek
Journal:  Ultrasonography       Date:  2020-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.